Vivo Capital’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Vivo Capital’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-62,306	Closed	-$1.83M	–	64
2021 Q2	$1.83M	Sell	62,306 -248,724	-80%	-$7.12M	0.08%	55
2021 Q1	$8.57M	Hold	311,030	–	–	0.3%	47
2020 Q4	$10.5M	Sell	311,030 -268,970	-46%	-$8.19M	0.47%	40
2020 Q3	$13.9M	Hold	580,000	–	–	0.8%	36
2020 Q2	$13.5M	Buy	+580,000	New	+$11.5M	0.96%	28

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vivo Capital's CALT Position: Q3 2021 in Review

Vivo Capital sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2021, closing a stake of 62,306 shares — an estimated $1.83M sold.

Vivo Capital first reported a position in CALT in Q2 2020 and held it in 5 quarters. The position peaked at $13.9M in Q3 2020. 13 funds tracked by Wall St. Rank hold CALT as of Q3 2021.

Vivo Capital reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2021 after selling out during the quarter.
Vivo Capital sold 62,306 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2021, an estimated $1.83M.
Vivo Capital first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2020 and held it in 5 quarters.
Vivo Capital's Calliditas Therapeutics AB American Depositary Shares position peaked at $13.9M in Q3 2020.
13 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2021.

Based on Vivo Capital's 13F filing for Q3 2021, filed 15 Nov 2021.